How does CMVL.F's PS Ratio compare to its peers?

CMVL.F is good value based on its Price-To-Sales Ratio (10.3x) compared to the peer average (25.4x).

How does CMVL.F's PS Ratio compare vs other companies in the US Biotechs Industry?

CMVL.F is good value based on its Price-To-Sales Ratio (10.3x) compared to the US Biotechs industry average (11.6x).

What is CMVL.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate CMVL.F's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of CMVL.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate CMVL.F's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Cellectis (OTCPK:CMVL.F) - Stock Price, News & Analysis

CMVL.F Stock Overview

A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. More details

CMVL.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 39.45% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Cellectis S.A. Competitors

Amarin

NasdaqGM:AMRN

US$225.7m

XOMA Royalty

NasdaqGM:XOMA

US$355.8m

Alector

NasdaqGS:ALEC

US$385.9m

Elutia

NasdaqCM:ELUT

US$142.4m

Price History & Performance

Summary of all time highs, changes and price drops for Cellectis
Historical stock prices
Current Share Price	€2.54
52 Week High	€3.58
52 Week Low	€0.95
Beta	3.22
11 Month Change	0%
3 Month Change	-14.19%
1 Year Change	n/a
33 Year Change	-80.46%
5 Year Change	-79.45%
Change since IPO	-45.23%

Recent updates

Shareholder Returns

	CMVL.F	US Biotechs	US Market
7D	0%	2.5%	2.2%
1Y	n/a	16.1%	31.6%

Return vs Industry: Insufficient data to determine how CMVL.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how CMVL.F performed against the US Market.

Price Volatility

Is CMVL.F's price volatile compared to industry and market?
CMVL.F volatility
CMVL.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CMVL.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine CMVL.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	219	Andre Choulika	www.cellectis.com

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Cellectis S.A. Fundamentals Summary

How do Cellectis's earnings and revenue compare to its market cap?
CMVL.F fundamental statistics
Market cap	US$202.13m
Earnings (TTM)	-US$78.90m
Revenue (TTM)	US$19.64m

10.3x

P/S Ratio

-2.6x

P/E Ratio

Is CMVL.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CMVL.F income statement (TTM)
Revenue	US$19.64m
Cost of Revenue	US$737.00k
Gross Profit	US$18.90m
Other Expenses	US$97.80m
Earnings	-US$78.90m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.79
Gross Margin	96.25%
Net Profit Margin	-401.86%
Debt/Equity Ratio	28.9%

How did CMVL.F perform over the long term?

See historical performance and comparison

CMVL.F Stock Overview

Rewards

Risk Analysis

Cellectis S.A. Competitors

NasdaqGM:AMRN

US$225.7m

NasdaqGM:XOMA

US$355.8m

NasdaqGS:ALEC

US$385.9m

NasdaqCM:ELUT

US$142.4m

Price History & Performance

Recent News & Updates

Cellectis Presents Multiple Strategies to Enhance Car T-Cell Efficacy in Solid Tumors at the SITC Annual Meeting

Cellectis S.A. to Report Q3, 2024 Results on Nov 04, 2024

Cibus, Inc. Achieves Positive Initial Field Trial Results for Stacked Gene Editing Herbicide Tolerant Traits in Rice

Cellectis Announces the Publication of A Scientific Article in Nature Communications

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

Recent updates

Cellectis Presents Multiple Strategies to Enhance Car T-Cell Efficacy in Solid Tumors at the SITC Annual Meeting

Cellectis S.A. to Report Q3, 2024 Results on Nov 04, 2024

Cibus, Inc. Achieves Positive Initial Field Trial Results for Stacked Gene Editing Herbicide Tolerant Traits in Rice

Cellectis Announces the Publication of A Scientific Article in Nature Communications

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

Cellectis Announces Chief Financial Officer Changes

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Cellectis S.A. Announces New Product Candidate Pipeline, and Manufacturing and Technologies

Cellectis S.A. Announces Preliminary Results from its Phase 1 Balli-01 Clinical Study of Ucart22 in Adults with R/R B-All Presented in Oral Session At 2020 Ash Annual Meeting

Cellectis S.A. to Report Q4, 2020 Results on Mar 04, 2021

Cytovia Therapeutics, Inc. and Cellectis Enter into Strategic Research and Development Collaboration

FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma

Cellectis Appoints Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer

Cellectis S.A. Appoints Jean-Pierre Garnier, Ph.D as Non-Executive Chairman of the Board of Directors

Cellectis S.A. to Report Q2, 2020 Results on Aug 05, 2020